Noveltreat 1.7 mg Pre-Filled Pen delivers of a GLP-1 receptor agonist, semaglutide in 0.75mL.
Noveltreat is indicated in India for chronic weight management in adults when coupled with a low-calorie diet and increased physical activity. Different strengths are available from 0.25mg to 2.4mg:
- 0.25mg
- 0.5mg
- 1mg
- 1.7mg
- 2.4mg
1.7mg dosage step is a part of the later dose-escalation phase before the standard treatment dose of 2.4mg maintenance. Semaglutide can suppress the sense of hunger, cause the feeling of satiety, limit food intake which altogether can assist in slow weight loss and maintenance of lost weight.
What is Noveltreat 1.7 mg used for?
Noveltreat 1.7mg is a semaglutide injection used as part of a chronic weight-management programme.
Semaglutide may help:
- Reduce hunger
- Increase fullness after meals
- Reduce food cravings
- Help control portion sizes
- Reduce overall calorie intake
- Support weight loss
- Help maintain weight loss during continued treatment
Medicament Healthdirect states that these medicines can suppress the appetite, and at the same time make a person satisfied and keep the feeling of being full for a long time. Medicinal treatment for weight loss usually goes together with lifestyle & behavioural changes.
How does Noveltreat 1.7mg work?
Noveltreat is a medication that contains semaglutide. This is a drug that targets GLP-1 receptors.
GLP-1 is a hormone related to appetite suppression and also has a role in gut activity and blood glucose control. Semaglutide mimics GLP-1 activity, which means that it can:
- Reduce appetite
- Increase satiety
- Reduce hunger
- Slow gastric emptying
- Reduce food intake
These effects can make it easier for some people to maintain a reduced-calorie diet.
The medicine does not replace healthy eating or physical activity.
Dosage
Noveltreat is designed to be increased gradually rather than started at the 1.7mg strength.
The weight-management dosing sequence is generally:
| Treatment stage | Weekly dose |
| Starting dose | 0.25mg |
| Early escalation | 0.5mg |
| Further escalation | 1mg |
| Later escalation | 1.7mg |
| Maintenance | 2.4mg |
Do not increase, decrease or extend your Noveltreat dose schedule without medical advice.
How to use Noveltreat 1.7 mg Pre-Filled Pen
Noveltreat 1.7 mg is administered as a subcutaneous injection once weekly.
Common injection areas include:
- Abdomen
- Thigh
- Upper arm
Semaglutide should not be injected into a vein or muscle.
Important instructions
- Use Noveltreat exactly as prescribed.
- Inject it once a week.
- Follow the instructions supplied with the specific pen.
- Check the pen before use.
- Do not use a damaged pen.
- Do not share the pen with another person.
- Dispose of the single-dose pen as instructed after use.
The product shown is labelled single-dose only and contains 1.7mg in 0.75mL.
Can Noveltreat 1.7 mg be taken with food?
Yes. Noveltreat is an injection, so it does not require fasting.
Semaglutide injections are generally compatible with eating meals but are also acceptable without them. Oral semaglutide tablet forms like Rybelsus need the patient to comply with specified rules regarding when not to eat (fasting), water, and time limits.
What happens during treatment with Noveltreat 1.7 mg?
Your weight loss may range from a few pounds to more significant changes. There are many factors which play a role here.
If your starting weight is much greater than the others, you will tend to lose more initially and then slowly afterwards. However, it’s not possible to predict exactly how long each level of weight loss will last for individuals.
Some people may lose weight and continue to maintain it for a long time, whereas others might go up and down quite regularly. It all depends upon your individual circumstances. If you do everything correctly, your diet & exercise plans, then you will likely get the most benefit out of it and keep on with it over time.
What if you miss a Noveltreat 1.7 mg dose?
According to the product information for Wegovy (semaglutide) in Australia, a missed dose can usually be administered within 5 days after the scheduled one.
However, if a missed injection is noticed more than 5 days after the prescribed day, simply skip the missed dose and resume your treatment on your regular scheduled day. Avoid taking two doses simultaneously.
In case of multiple doses missed, it’s advisable to consult your doctor or any other medical provider before you resume your medication, as there is a chance the dose level may have to be changed.
Common side effects
Gastrointestinal side effects are common with semaglutide, especially during dose escalation.
Possible side effects include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal pain or discomfort
- Bloating
- Indigestion
- Headache
- Reduced appetite
- Burping
These symptoms may become more noticeable after moving to a higher dose.
When should you seek medical attention?
Contact a healthcare professional if you develop:
- Severe or persistent abdominal pain
- Repeated vomiting
- Severe or ongoing diarrhoea
- Signs of dehydration
- Symptoms of gallbladder disease
- A serious allergic reaction
- Sudden or significant changes in vision
Severe abdominal pain can be a warning sign of pancreatitis. Persistent vomiting or diarrhoea can cause dehydration and may affect kidney function.
Precautions
Tell your doctor if you have or have previously had:
- Pancreatitis
- Gallstones or gallbladder disease
- Severe gastrointestinal problems
- Gastroparesis or delayed stomach emptying
- Kidney disease
- Liver disease
- Diabetic retinopathy
- A serious allergy to semaglutide
- Medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Your doctor needs to be informed about all prescription drugs that you take (not only semaglutide if prescribed), but also all the other over-the-counter medications and supplements you are using.
Special monitoring might be required when semaglutide is prescribed together with insulin or sulfonylurea drugs due to the fact that such combinations elevate the chance of hypoglycemia.
Noveltreat 1.7 mg and pregnancy
Noveltreat should not be used during pregnancy.
If you are planning a pregnancy, speak with your doctor before using semaglutide. Australian product information for Wegovy recommends stopping semaglutide at least 2 months before a planned pregnancy.
Contact your healthcare professional if you become pregnant while using Noveltreat.
Noveltreat 1.7 mg and breastfeeding
The use of semaglutide during breastfeeding should be discussed with a healthcare professional.
Do not start or continue Noveltreat while breastfeeding unless your doctor has specifically advised you to do so.
Noveltreat 1.7 mg interactions
Tell your doctor about all medicines and supplements you use.
Semaglutide can delay gastric emptying and may affect the absorption of some oral medicines.
Particular attention may be needed with:
- Insulin
- Sulfonylureas
- Other diabetes medicines
- Other GLP-1 receptor agonists
- Other semaglutide-containing products
- Medicines requiring careful blood-level monitoring
Do not combine Noveltreat with another semaglutide product or GLP-1 receptor agonist unless your healthcare professional specifically tells you to.
How to store It
Noveltreat 1.7 mg should be stored according to the manufacturer’s instructions. For comparable Australian-registered semaglutide 1.7mg products, the recommended storage is:
- 2°C to 8°C
- Protect from light
- Do not freeze
- Keep refrigerated
- Keep out of reach of children
The Noveltreat product should remain in its original packaging and should not be used if it has been frozen or stored outside the manufacturer’s recommended conditions without confirmation from a pharmacist.
Noveltreat 1.7 mg and weight management
The 1.7mg dose is an advanced escalation dose, not normally the starting dose.
Towards this phase, a few individuals may notice appetite and food habits have been impacted more than low dose levels. Notwithstanding a general trend for slimming down is still far from identical for every person.
Low-calorie diets and exercise are still part of the solution though weight-loss medications can be supportive when it comes to managing body weight. Weight loss medicines, according to Healthdirect, are not a treatment for obesity alone.
FAQs
1. Can Noveltreat 1.7 mg cause frequent burping?
Yes. Belching (burping) sometimes occurs together with semaglutide as the drug may influence how quickly the stomach contents leave and also how gut contents move around.
If you are experiencing excessive belching, that is not improving and/or associated with a substantial abdominal pain or vomiting that takes place several times you should consult a health care specialist.
2. Can Noveltreat 1.7 mg affect how much water I need to drink?
Semaglutide itself does not establish a specific daily water requirement. However, nausea, vomiting or diarrhoea can increase fluid loss, while reduced appetite may also mean you consume less fluid through food and drinks. Maintaining adequate hydration is important, particularly if gastrointestinal symptoms occur.
3. Can Noveltreat 1.7 mg be used with medicines for high blood pressure?
It may be possible, but your doctor should review your complete medication list. Weight loss and changes in food and fluid intake can alter blood pressure over time, so blood pressure medicines may sometimes require monitoring or adjustment.
4. What if my appetite becomes very low on Noveltreat 1.7mg?
A reduction in appetite is part of how semaglutide works, but extremely low appetite that makes it difficult to eat adequately, maintain hydration or obtain necessary nutrients should be discussed with your healthcare professional. Do not deliberately restrict food excessively to accelerate weight loss.
5. Can Noveltreat 1.7 mg be used if I have a history of gallstones?
A history of gallstones does not automatically mean that semaglutide is unsuitable, but it should be discussed with your doctor. Semaglutide treatment can be associated with gallbladder problems, including gallstones and inflammation of the gallbladder. Seek medical attention for persistent upper abdominal pain, fever or yellowing of the skin or eyes.
References
- Healthdirect Australia – Wegovy (Healthdirect)
- Healthdirect Australia – Weight loss medicine (Healthdirect)
- TGA – Wegovy Product Information (Therapeutic Goods Administration (TGA))
Medical disclaimer: This information is for educational purposes only and does not replace advice from a doctor or pharmacist. Always follow the prescription, current product information and instructions supplied with your medicine.
